Nasdaq GlobeNewswire

Biogen Appoints Daniel Karp as EVP, Corporate Development

Del
  • Seasoned executive brings strong track record of success leading licensing and M&A transactions

CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) --  Biogen (Nasdaq:BIIB) announced today the appointment of Daniel Karp as Executive Vice President, Corporate Development effective June 11, 2018.

Karp will lead the newly created Corporate Development function, which will include corporate and business development and corporate strategy. He will be a member of the Executive Committee and report directly to Michel Vounatsos, Biogen's Chief Executive Officer.  

"We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience," Vounatsos said. "Daniel's solid experience from Pfizer combined with his scientific and business education will serve him well in this exciting position as we aim to further build our pipeline and portfolio to tackle unmet needs in neurological diseases."

Daniel joins Biogen from Pfizer where he most recently was Vice President, Worldwide Business Development and head of business development for R&D.  In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer's research portfolio.  In over a decade at Pfizer, he held corporate and business development roles spanning rare diseases, gene therapy, vaccines, oncology and specialty care, with experience including mergers and acquisitions, licensing and scientific collaborations. In recent years, he has been involved in several high-profile acquisitions and led business development organizations that executed hundreds of agreements, licenses and collaborations. His experience also includes healthcare and life sciences strategy consulting.

"It's a privilege to join Biogen, a true leader in neuroscience," Karp said.  "I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases."

Karp holds a BS in Biology from Duke University and an MBA from the Wharton School of Business at the University of Pennsylvania.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor 
This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen's business activities, our strategy and plans, the potential of our commercial business and pipeline programs and the expected benefits from Karp's appointment as our Executive Vice President, Corporate Development. These forward-looking statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "except," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; potential future healthcare reforms; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact:

Biogen
MEDIA:
David Caouette, +1 617-679-4945
public.affairs@biogen.com
or
INVESTORS:
Mike Henke, +1 781-464-2442
IR@biogen.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biogen Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Platinum Equity to Sell Worldwide Flight Services for €1.2 Billion19.6.2018 15:00Pressemelding

Successful investment adds to Platinum Equity's continued momentum in Europe LOS ANGELES, June 19, 2018 (GLOBE NEWSWIRE) -- Platinum Equity today announced it has signed a definitive agreement to sell Worldwide Flight Services (WFS) to affiliates of Cerberus Capital Management, L.P. in a transaction valued at approximately €1.2 billion. The sale is expected to close during Q4 2018, subject to regulatory approval and certain closing conditions. Since Platinum Equity acquired the company in 2015, WFS has grown significantly, both organically and through a transformative add-on acquisition, and is now the world's largest air cargo handler and one of the world's leading providers of ground handling and technical services, with annual revenues of more than €1.2 billion. "Through a combination of growth and operational initiatives, WFS has evolved and expanded significantly over the past three years and today enjoys record top-line and earnings performance," said Platinum Equity Partner Loui

Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00Pressemelding

SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00Pressemelding

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P

Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44Pressemelding

YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon

Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00Pressemelding

AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by

PubMatic Launches PubMatic Cloud to Evolve the SSP Business Model19.6.2018 09:00Pressemelding

New offering provides publishers and tech companies with a transparent alternative to revenue shares REDWOOD CITY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced the launch of PubMatic Cloud for publishers and tech companies looking to implement and control their own programmatic technology. By accessing PubMatic's technology, global infrastructure and demand connections on a platform-as-a-service (PaaS) basis, clients are able to achieve full transparency and achieve greater control over their programmatic monetization. As programmatic trading becomes mainstream, innovations such as header bidding and fraud controls have resulted in gains for publishers. However, it has also contributed to the ballooning of infrastructure costs and overhead to manage integrations with the buy-side and third-party technology vendors as well as continuously evolving technology. The ability to keep pace

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom